PF-Atlas › Clinical Trials › NCT03798119

TAF Switch in F3/4 CHB pt With Partial Response to NUC

Tenofovir Alafenamide · Phase 4

Registry ID
NCT03798119
Phase
Phase 4
Status
Unknown
Drug / intervention
Tenofovir Alafenamide
Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Start
2019-02-25
Enrollment
80
Locations
1

About this trial

A total of 80 adult chronic hepatitis B patients with advanced liver fibrosis (including fibrosis stage 3 and cirrhosis), who are currently on nucleot(s)ide analogs (except tenofovir alafenamide) therapy with detectable HBV DNA after 52 weeks of therapy will switch prior NUCs to TAF 25 mg/day for 96 weeks

View NCT03798119 on ClinicalTrials.gov →

Explore related

All Tenofovir Alafenamide trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03798119 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.